Stratifin Promotes Hepatocellular Carcinoma Progression by Modulating the Wnt/β-Catenin Pathway

Table 1

Clinicopathological features of 34 HCC patients between SFN high and low expression cohorts.

Features	qRT-PCR		value
	Low ()	High ()
Gender, n
Male	15	13	0.656
Female	2	4
Age, years
≤50	7	9	0.732
>50	10	8
HBV infection, n
Positive	16	15	1.000
Negative	1	2
AFP, ng/ml
≤400	7	12	0.166
>400	10	5
Tumor number, n
Solitary	16	15	1.000
Multiple	1	2
Tumor size, cm
≤5	14	6	0.013*
>5	3	11
Vascular invasion, n
Yes	4	11	0.037*
None	13	6
Tumor differentiation, n
Well/moderate	17	9	0.003*
Poor	0	8
Liver cirrhosis, n			0.708
Yes	13	11
None	4	6
AJCC TNM stage, n
I/II	14	6	0.013*
III/IV	3	11

AFP: alpha-fetoprotein; AJCC: American Joint Committee on Cancer; HBV: hepatitis B virus; HCC: hepatocellular Carcinoma; SFN: stratifin. *. Fisher exact test was used in all analyses.